- Home
- TRC vs BNTC Comparison
TRC vs BNTC Comparison
Compare TRC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- BNTC
- Stock Information
- Founded
- TRC 1843
- BNTC 1995
- Country
- TRC United States
- BNTC United States
- Employees
- TRC N/A
- BNTC N/A
- Industry
- TRC Real Estate
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- BNTC Health Care
- Exchange
- TRC Nasdaq
- BNTC Nasdaq
- Market Cap
- TRC 427.8M
- BNTC 352.5M
- IPO Year
- TRC N/A
- BNTC N/A
- Fundamental
- Price
- TRC $16.50
- BNTC $13.63
- Analyst Decision
- TRC
- BNTC Strong Buy
- Analyst Count
- TRC 0
- BNTC 7
- Target Price
- TRC N/A
- BNTC $24.71
- AVG Volume (30 Days)
- TRC 134.5K
- BNTC 34.2K
- Earning Date
- TRC 05-08-2025
- BNTC 05-16-2025
- Dividend Yield
- TRC N/A
- BNTC N/A
- EPS Growth
- TRC 422.75
- BNTC N/A
- EPS
- TRC 0.08
- BNTC N/A
- Revenue
- TRC $42,689,000.00
- BNTC N/A
- Revenue This Year
- TRC $0.64
- BNTC N/A
- Revenue Next Year
- TRC N/A
- BNTC N/A
- P/E Ratio
- TRC $213.48
- BNTC N/A
- Revenue Growth
- TRC 7.04
- BNTC N/A
- 52 Week Low
- TRC $14.71
- BNTC $5.74
- 52 Week High
- TRC $19.82
- BNTC $16.90
- Technical
- Relative Strength Index (RSI)
- TRC 46.57
- BNTC 49.98
- Support Level
- TRC $16.73
- BNTC $13.35
- Resistance Level
- TRC $17.38
- BNTC $15.69
- Average True Range (ATR)
- TRC 0.49
- BNTC 0.74
- MACD
- TRC -0.05
- BNTC -0.03
- Stochastic Oscillator
- TRC 39.11
- BNTC 20.46
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.